Retatrutide: The Triple-Hormone GLP-1 That May Beat Semaglutide & Tirzepatide

The next frontier in GLP-1 treatment

Just as tirzepatide improved on semaglutide by targeting two hormone receptors instead of one, retatrutide takes the next leap: targeting three. This investigational medication from Eli Lilly activates GLP-1, GIP, and glucagon receptors simultaneously, and early results suggest it may produce the greatest weight loss of any GLP-1 medication — up to 24.2% in Phase 2 trials.

While not yet FDA-approved, retatrutide represents the future of metabolic medicine. Here is everything we know so far.

Explore current GLP-1 options

How retatrutide works: the triple agonist advantage

Hormone Receptor	What It Does	Effect on Weight Loss	Other Benefits
GLP-1 receptor	Reduces appetite, slows gastric emptying	Appetite suppression, reduced food intake	Improves glucose, cardiovascular protection
GIP receptor	Enhances insulin secretion, improves fat metabolism	Improved fat utilization, reduced fat storage	Better glucose control, reduced inflammation
Glucagon receptor	Increases energy expenditure, promotes fat burning	More calories burned, enhanced fat loss	Liver fat reduction, improved lipid profile
Triple combination	All three mechanisms simultaneously	Maximum weight loss potential	Comprehensive metabolic improvement
Get my GLP-1 treatment plan

Retatrutide vs semaglutide vs tirzepatide

Feature	Semaglutide (Wegovy)	Tirzepatide (Zepbound)	Retatrutide (investigational)
Hormone targets	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Average weight loss	~15%	~20 to 22.5%	~24.2% (Phase 2 data)
Administration	Weekly injection	Weekly injection	Weekly injection (expected)
FDA approval	Approved (obesity, CV)	Approved (obesity, OSA)	Not yet approved
Cardiovascular benefits	SELECT trial: 20% CV reduction	SURPASS: significant	Expected (trials ongoing)
Side effects	GI (nausea, vomiting, diarrhea)	GI (similar to semaglutide)	GI (similar, plus glucagon effects)
Expected availability	Available now	Available now	2026 to 2027 (estimated)

Phase 2 trial results: the TRIUMPH data

Dose	Weight Loss at 24 weeks	Weight Loss at 48 weeks	% Achieving 15%+ Loss	% Achieving 20%+ Loss
1 mg	~7%	~9%	~20%	~5%
4 mg	~12%	~17%	~55%	~30%
8 mg	~17%	~22%	~75%	~55%
12 mg	~18%	~24.2%	~85%	~70%
Placebo	~2%	~2.5%	~0%	~0%

Get started with GLP-1 treatment

The glucagon advantage: why three is better than two

Benefit	Mechanism	Unique to Retatrutide?	Impact
Increased energy expenditure	Glucagon receptor activation increases metabolic rate	Yes — not in semaglutide or tirzepatide	More calories burned at rest
Enhanced fat oxidation	Glucagon promotes fat burning over storage	Yes	Greater fat loss, less muscle loss
Liver fat reduction	Glucagon directly reduces liver fat production	Enhanced vs other GLP-1s	Significant for fatty liver disease
Improved lipid profile	Glucagon reduces VLDL and triglycerides	Enhanced	Better cholesterol improvement
Thermogenic effect	Glucagon increases body heat production	Yes	Additional calorie burning

Side effect profile of retatrutide

Side Effect	Frequency	Severity	Comparison to Other GLP-1s
Nausea	30 to 50%	Mild to moderate	Similar to tirzepatide
Diarrhea	15 to 30%	Mild to moderate	Similar
Vomiting	10 to 20%	Mild to moderate	Similar
Constipation	10 to 20%	Mild	Similar
Injection site reactions	5 to 10%	Mild	Similar
Increased heart rate	Variable	Mild (2 to 6 bpm)	Slightly more than semaglutide
Skin-related (glucagon effect)	Being monitored	Mild	Unique — under investigation

Discuss GLP-1 options with a provider

Development timeline and expected approval

Phase	Status	Timeline	Key Milestone
Phase 1	Completed	2020 to 2021	Safety and dosing established
Phase 2	Completed	2022 to 2024	24.2% weight loss demonstrated
Phase 3 (TRIUMPH)	Ongoing	2024 to 2026	Confirming efficacy and safety in larger population
FDA filing	Expected	2025 to 2026	New Drug Application submission
FDA review	Expected	6 to 12 months after filing	FDA evaluates safety and efficacy
Approval (if successful)	Expected	Late 2026 to 2027	Available by prescription

Frequently asked questions

What is retatrutide?

Retatrutide is an investigational triple-hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it is being studied for obesity and type 2 diabetes. Early trial results show weight loss of up to 24% — potentially exceeding both semaglutide (15%) and tirzepatide (22.5%). It is not yet FDA-approved but is expected to file for approval in 2025 to 2026.

How does retatrutide compare to semaglutide and tirzepatide?

Retatrutide targets three hormone receptors (GLP-1, GIP, glucagon) while semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP. The addition of glucagon receptor agonism is expected to increase energy expenditure and fat burning, potentially producing greater weight loss. Phase 2 results showed up to 24% weight loss at 48 weeks, compared to 15% for semaglutide and 22.5% for tirzepatide.

When will retatrutide be available?

Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program). If trials complete successfully, Eli Lilly is expected to file for FDA approval in 2025 to 2026. If approved, retatrutide could be available by late 2026 or 2027. The exact timeline depends on trial results and FDA review process.

What are the side effects of retatrutide?

Side effects are similar to other GLP-1 medications: nausea, vomiting, diarrhea, constipation, and injection site reactions. The glucagon receptor component may cause additional effects related to increased energy expenditure. Phase 2 data shows the side effect profile is comparable to tirzepatide, with most adverse events being mild to moderate GI symptoms.

How much weight can you lose on retatrutide?

Phase 2 trial results showed weight loss of up to 24.2% at 48 weeks at the highest dose (12 mg). This is the highest weight loss reported for any GLP-1 medication in clinical trials. Phase 3 trials are confirming these results. If approved, retatrutide could become the most effective weight loss medication available.

Why does retatrutide target three hormones?

Each hormone target serves a purpose: GLP-1 reduces appetite and improves glucose, GIP enhances insulin secretion and fat metabolism, and glucagon increases energy expenditure and fat burning. The triple combination is designed to produce greater weight loss than targeting one or two receptors alone. The glucagon component specifically may help burn more calories.

Will retatrutide replace semaglutide and tirzepatide?

Not necessarily replace, but it may become the preferred option for people needing maximum weight loss. Semaglutide and tirzepatide will likely remain important options, especially for patients who respond well to them or have specific conditions like cardiovascular disease (semaglutide) or sleep apnea (tirzepatide). Retatrutide will add another option, not replace existing treatments.

Should I wait for retatrutide or start semaglutide/tirzepatide now?

Do not wait. If you qualify for GLP-1 treatment now, starting semaglutide or tirzepatide can deliver significant health benefits immediately. Retatrutide may not be available until 2026 to 2027, and waiting means losing valuable time for weight loss and health improvement. You can always switch to retatrutide later if it becomes available and offers advantages for your situation.

Start my weight loss journey now

Conclusion

Retatrutide represents the exciting future of GLP-1 treatment. By targeting three hormone receptors instead of one or two, it may achieve the greatest weight loss of any medication in this class — up to 24.2% in Phase 2 trials. The addition of glucagon receptor agonism provides a unique fat-burning mechanism not found in current GLP-1s. While we await Phase 3 results and FDA approval (expected 2026 to 2027), the current options — semaglutide and tirzepatide — remain highly effective and available now. If you are considering GLP-1 treatment, do not wait for retatrutide. Start your journey now and switch later if retatrutide proves to be a better option for you.